Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Withdrawn 1Unknown 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4Other hematologic neoplasm 4

Conditions

Multiple Myeloma 234Precursor Cell Lymphoblastic Leukemia-Lymphoma 69Recurrence 36Burkitt Lymphoma 34Leukemia 32Lymphoma 30Neoplasms, Plasma Cell 22Lymphoma, Non-Hodgkin 19Immunoglobulin Light-chain Amyloidosis 18Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 17Lymphoma, Mantle-Cell 16Neoplasms 15Nausea 15Lymphoma, Large B-Cell, Diffuse 15Vomiting 14Hodgkin Disease 13Breast Neoplasms 12Waldenstrom Macroglobulinemia 11Leukemia, Biphenotypic, Acute 11Lymphoma, Follicular 10Lymphoma, B-Cell, Marginal Zone 10Amyloidosis 10Lung Neoplasms 9Smoldering Multiple Myeloma 8Prostatic Neoplasms 8Neoplasm Metastasis 8Leukemia, Myeloid, Acute 8Hematologic Neoplasms 7Blast Crisis 7Lymphoma, T-Cell, Cutaneous 6

Interventions

Dexamethasone 10fludarabine phosphate 9Melphalan 9fludarabine 8Whole-Body Irradiation 7Peripheral Blood Stem Cell Transplantation 7Lenalidomide 7Cyclophosphamide 7Mycophenolic Acid 6Bortezomib 6Tacrolimus 5Calcium Dobesilate 4filanesib 3dexamethasone acetate 3dexamethasone 21-phosphate 3daratumumab 3carfilzomib 3auricularum 3Stem Cell Transplantation 3Sirolimus 3Filgrastim 3liposomal doxorubicin 2ixazomib 2Steroids 2Injections, Subcutaneous 2Granulocyte Colony-Stimulating Factor 2Etoposide 2Cytarabine 2Cyclosporine 2Carmustine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Leukemia, Plasma Cell × Calcium Dobesilate × Clear all
NCT07605416 2026-05-26

Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial

National Cancer Institute (NCI)

Phase 2 Not yet recruiting
74 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell

NCT02547662 2023-10-30

Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia

Mayo Clinic

Phase 2 Completed
17 enrolled 13 charts
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Plasmacytoma

NCT03591744 2018-12-19

Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia

City of Hope Medical Center

Phase 1 Withdrawn
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell

NCT01328236 2011-09-22

Bortezomib

Clinical Service, China

Phase 2 Unknown
20 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡